Immune checkpoint inhibitor‑based vs. non‑immunotherapy subsequent treatment after progression on first‑line chemoimmunotherapy in extensive‑stage small cell lung cancer: A meta‑analysis
. First‑line chemoimmunotherapy is currently a standard treatment for extensive‑stage small cell lung cancer (ES‑SCLC), but the value of immune checkpoint inhibitor (ICI)‑based subsequent treatment after progression remains uncertain. The present meta‑analysis assessed the efficacy and safety of ICI‑based vs. non‑immun...